# Channel Therapeutics Corporation (CHRO)

Source: https://www.quantisnow.com/company/CHRO
Generated: 2026-11-10T21:09:32.295Z

- Ticker: CHRO
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2024

## Latest CHRO news and filings

- 2025-07-10 20:15 UTC [SEC Form D] [SEC Form D filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-d-filed-by-channel-therapeutics-corporation-6116892)
- 2025-07-10 12:00 UTC [Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum](https://www.quantisnow.com/insight/pelthos-therapeutics-launches-zelsuvmi-berdazimer-topical-gel-103-the-first-6116210)
- 2025-07-08 20:05 UTC [SEC Form SCHEDULE 13G filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-channel-therapeutics-corporation-6114177)
- 2025-07-08 01:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Baxter Richard B](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-baxter-richard-b-6113266)
- 2025-07-08 01:46 UTC [SEC Form 4] [SEC Form 4 filed by Director Greenleaf Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-greenleaf-peter-6113265)
- 2025-07-08 01:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Pauls Matthew](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pauls-matthew-6113263)
- 2025-07-08 01:44 UTC [SEC Form 4] [SEC Form 4 filed by CFO, Treas & Secty Francis Knuettel Ii](https://www.quantisnow.com/insight/sec-form-4-filed-by-cfo-treas-secty-francis-knuettel-6113262)
- 2025-07-08 01:43 UTC [SEC Form 4] [SEC Form 4 filed by Director Davis Todd C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-davis-todd-c-6113261)
- 2025-07-08 01:42 UTC [SEC Form 4] [SEC Form 4 filed by Director Friedberg Ezra M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-friedberg-ezra-m-6113259)
- 2025-07-08 01:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Malamut Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-malamut-richard-6113257)
- 2025-07-08 01:40 UTC [SEC Form 3] [SEC Form 3 filed by new insider Greenleaf Peter](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-greenleaf-peter-6113256)
- 2025-07-08 01:39 UTC [SEC Form 3] [SEC Form 3 filed by new insider Pauls Matthew](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-pauls-matthew-6113255)
- 2025-07-08 01:37 UTC [SEC Form 3] [SEC Form 3 filed by new insider Baxter Richard B](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-baxter-richard-b-6113254)
- 2025-07-04 01:07 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-channel-therapeutics-corporation-6111848)
- 2025-07-04 01:05 UTC [SEC Form 4] [Director Friedberg Ezra M converted options into 80,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-friedberg-ezra-m-converted-options-into-80000-shares-sec-6111847)
- 2025-07-04 01:04 UTC [SEC Form 4] [Chief Financial Officer Francis Knuettel Ii converted options into 10,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-francis-knuettel-ii-converted-options-into-10000-6111841)
- 2025-07-04 01:02 UTC [SEC Form 4] [Director Davis Todd C converted options into 1,500,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-davis-todd-c-converted-options-into-1500000-shares-sec-6111839)
- 2025-07-03 20:05 UTC [SEC Form SCHEDULE 13D filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-channel-therapeutics-corporation-6110872)
- 2025-07-03 13:33 UTC [SEC Form 4] [Large owner Ligand Pharmaceuticals Inc converted options into 1,500,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-ligand-pharmaceuticals-inc-converted-options-into-1500000-shares-6110282)
- 2025-07-03 13:28 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ligand Pharmaceuticals Inc](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ligand-pharmaceuticals-inc-6110273)
- 2025-07-02 21:22 UTC [SEC Form 8-K] [Channel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/channel-therapeutics-corporation-filed-sec-form-8-k-entry-into-a-6109309)
- 2025-07-02 11:00 UTC [Leadership Update] [Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement](https://www.quantisnow.com/insight/pelthos-therapeutics-completes-merger-with-channel-therapeutics-and-closes-501-6107054)
- 2025-06-27 13:15 UTC [Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement](https://www.quantisnow.com/insight/channel-therapeutics-announces-reverse-common-stock-split-in-conjunction-with-6101456)
- 2025-05-27 21:07 UTC [SEC Form DEFM14C filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-defm14c-filed-by-channel-therapeutics-corporation-6059672)
- 2025-05-14 12:00 UTC [Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models](https://www.quantisnow.com/insight/channel-therapeutics-announces-positive-efficacy-results-for-the-treatment-of-6037617)
- 2025-05-13 20:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-channel-therapeutics-corporation-6036324)
- 2025-05-09 21:30 UTC [SEC Form PREM14C filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-prem14c-filed-by-channel-therapeutics-corporation-6031096)
- 2025-05-01 21:05 UTC [SEC Form 8-K] [Channel Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/channel-therapeutics-corporation-filed-sec-form-8-k-regulation-fd-disclosure-6014115)
- 2025-05-01 21:00 UTC [Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules](https://www.quantisnow.com/insight/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-6014042)
- 2025-04-17 10:11 UTC [SEC Form 8-K] [Channel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/channel-therapeutics-corporation-filed-sec-form-8-k-entry-into-a-5990965)
- 2025-04-17 10:00 UTC [Conference Announcement] [Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics](https://www.quantisnow.com/insight/ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-5990885)
- 2025-04-16 01:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Simmons Chia-Lin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-simmons-chia-lin-5989172)
- 2025-04-16 01:30 UTC [SEC Form 4] [SEC Form 4 filed by CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceo-pres-cfo-treas-secty-5989171)
- 2025-03-27 21:08 UTC [SEC Form 10-K] [SEC Form 10-K filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-channel-therapeutics-corporation-5963619)
- 2025-03-03 12:00 UTC [SEC Form 8-K] [Channel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/channel-therapeutics-corporation-filed-sec-form-8-k-entry-into-a-5918959)
- 2025-02-14 18:09 UTC [SEC Form SCHEDULE 13G filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-channel-therapeutics-corporation-5889847)
- 2024-12-20 14:00 UTC [Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine](https://www.quantisnow.com/insight/channel-therapeutics-highlights-differences-between-nav17-and-nav18-in-light-5821587)
- 2024-12-20 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-effect-filed-by-channel-therapeutics-corporation-5821237)
- 2024-12-18 13:30 UTC [Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model](https://www.quantisnow.com/insight/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-5818186)
- 2024-12-11 21:06 UTC [SEC Form POS AM filed by Channel Therapeutics Corporation](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-channel-therapeutics-corporation-5809386)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CHRO
- Earnings history: https://www.quantisnow.com/earnings/CHRO
- Dividend history: https://www.quantisnow.com/dividends/CHRO
- Insider transactions: https://www.quantisnow.com/insiders/CHRO
- Options chain: https://www.quantisnow.com/options/CHRO
- SEC 8-K filings only: https://www.quantisnow.com/company/CHRO/8-k
- RSS and alerts for CHRO: https://www.quantisnow.com/docs/rss-feeds.md